The c-src and c-yes proto-oncogenes encode 60 000 and 62 000 Dalton non-receptor tyrosine kinases of the Src family, pp60
, respectively. These kinases are over 80% homologous outside of their unique amino termini, yet several studies suggest that dierences exist in the regulation, activation, and function of cSrc and cYes. The determinants of speci®city in signaling between these proteins, however, remain unclear. In order to investigate the roles of the Src Homology (SH) 3 and 2 domains in mediating signaling speci®city between cSrc and cYes, chimeras were created in which the SH3 and/or SH2 domains of cSrc or the fully activated variant Src 527F were replaced by the corresponding domains of cYes. These constructs were used to assess the eects of the Yes SH3 and SH2 domains on the ability of Src to form stable complexes with and induce tyrosine phosphorylation of Src SH3 and SH2 domain binding partners in vivo. Both the Yes SH3 and SH2 domains were found to alter the capacity of Src to form stable associations with heterologous proteins. The Yes SH3 domain was unable to anity absorb the Src SH3/SH2 binding partner AFAP-110 from COS-1 cell lysates, and chimeric constructs of Src 527F containing the cYes SH3 domain were unable to eciently coimmunoprecipitate with AFAP-110 from chicken embryo ®broblasts. Interactions with the Src SH2 domain binding partner pp130cas were unaected. Additionally, only chimeras containing the cYes SH2 domain were able to co-immunoprecipitate with an unidenti®ed 87 kDa tyrosine-phosphorylated protein. These results indicate that the SH3 and SH2 domains are capable of directing speci®city in substrate binding between Src and Yes, suggesting potential mechanisms for generating speci®city in signaling between these two highly related non-receptor tyrosine kinases. Oncogene (2000) 19, 155 ± 160.
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The Src family of non-receptor tyrosine kinases is comprised of nine members (Src, Yes, Fgr, Fyn, Lyn, Lck, Hck, Blk and Yrk) that share amino acid homology and a common domain architecture, consisting of four regions of Src homology (SH1-4) and a unique domain (Brickell, 1992) . Src family kinases are involved in many signal transduction pathways, in¯uencing such diverse cellular processes as cell division, dierentiation, survival, adhesion, and motility (Thomas and Brugge, 1997) . pp60 c-src and pp62 c-yes are of particular interest due to their frequent activation in several human cancers, most notably colon carcinoma, in which the activity of both kinases is commonly up-regulated (Cartwright et al., 1994 (Cartwright et al., , 1989 Park et al., 1993; Pena et al., 1995) . pp60 c-Src and pp62 c-yes are two of the most highly homologous members of the Src family. They share greater than 80% amino acid homology outside of their unique domains (Kitamura et al., 1982) and are both expressed throughout several vertebrate tissues, with particularly high levels in brain and platelets (Kefalas et al., 1995; Zhao et al., 1990) . cSrc and cYes are also activated in response to many of the same extracellular stimuli (Courtneidge et al., 1993; Fuhrer and Yang, 1996b; Kypta et al., 1990; Tsygankova et al., 1998) , at the same points in the cell cycle (Roche et al., 1995) , and are at least partially able to functionally compensate for each other in the event that one of the kinases is missing or non-functional (Roche et al., 1995; Stein et al., 1994) .
Despite the similarities between cSrc and cYes, dierences in the expression, regulation, and function of these two proteins have been demonstrated (Fuhrer and Yang, 1996a; Marchetti et al., 1998; Park and Cartwright, 1995; Zhao et al., 1993) . Single gene knockouts of either the c-src or c-yes gene in mice provide strong evidence for speci®c roles performed by cSrc and cYes, as the loss of either gene results in a unique phenotype. The loss of the c-src gene results in osteopetrosis due to a defect in the ability of the osteoclasts to reabsorb bone (Soriano et al., 1991) , and the loss of the c-yes gene results in a reduction in IgA levels in secreted¯uids, as cYes has been demonstrated to play a key role in IgA transcytosis mediated by the polyimmunoglobulin receptor (Luton et al., 1998) .
To date, the establishment of functional and regulatory dierences between cSrc and cYes have not revealed which functional domain or domains are responsible for directing signaling speci®city between these two highly related, non-receptor tyrosine kinases. Two potential candidates for mediating speci®city in signaling between cSrc and cYes are the SH3 and SH2 domains. The SH3 domain directs speci®c interactions by binding to proline rich sequences in target proteins, while the SH2 domain recognizes a phosphotyrosine moiety and the surrounding three or four amino acids (Kuriyan and Cowburn, 1997; Sudol, 1998) . It has been demonstrated that cSrc will phosphorylate many substrates on tyrosine residues that represent potential SH2 binding motifs (Songyang et al., 1995; Zhou and Cantley, 1995) . Replacement of the Abl tyrosine kinase SH2 domain with a heterologous SH2 domain alters the Abl-induced tyrosine-phosphorylation pro®le of cellular proteins in vivo (Mayer and Baltimore, 1994), while Weng et al. (1994) demonstrated that in vivo Src phosphorylation of several Src SH3 domain binding partners was dependent upon the integrity of the Src SH3 domain. These data indicate that, in addition to simply directing protein/protein interactions, the SH3 and SH2 domains may be involved in selecting substrates for tyrosine phosphorylation.
The 110 000 Dalton actin ®lament associated protein (AFAP-110) and the 130 000 Dalton Crk associated Src substrate (pp130cas) are two well-characterized tyrosine-phosphorylated substrates that form a stable complex with activated forms of Src, e.g., Src 527F , through SH3 and SH2 domain interactions (Schaller et al., 1993) . Stable complex formation between pp130cas and activated forms of Src are dependent primarily upon the integrity of the SH2 domain (Kanner et al., 1991; Sakai et al., 1994) , although it is also capable of binding the Src SH3 domain (Nakamoto et al., 1996) . Interactions between AFAP-110 and Src 527F are modulated by both the SH3 and SH2 domains, and disruption of either interaction is sucient to abrogate stable complex formation between these two proteins (Kanner et al., 1991; Guappone and Flynn, 1997; Guappone et al., 1998) . Mutations in the Src SH3 domain or the SH3-binding motif of AFAP-110 also inhibit phosphorylation of AFAP-110 by Src in vivo (Kanner et al., 1991; Guappone and Flynn, 1997) , indicating that SH3 domain interactions are important for presenting AFAP-110 for tyrosine-phosphorylation. vYes is unable to induce high levels of phosphorylation of either AFAP-110 or pp130cas proteins in vivo (Kanner et al., 1990) , thus one possible explanation of this data is that vYes is unable to form suciently high anity SH3 and/or SH2 domain interactions with AFAP-110 and pp130cas to allow ecient substrate presentation in vivo.
In order to explore this possibility, the relative anities of the cSrc and cYes SH3 domains for AFAP-110 were compared in vitro. The SH3 and SH2 domains are well conserved between cYes and vYes, thus the cYes SH3 and SH2 domains were used throughout this report. Lysates from Cos-1 cells overexpressing AFAP-110 were incubated with GST, GST-SH3 Src or GST-SH3 Yes fusion proteins immobilized on glutathione-coated sepharose beads. AFAP-110 was eciently absorbed by GST-SH3 Src , however, the levels of AFAP-110 absorbed by GST-SH3 Yes more closely approximated background levels absorbed by GST alone (Figure 1a ). Src and Yes SH3 absorbtions were performed from aliquots of the same cell lysates, thus dierences in the amount of AFAP-110 absorbed were not due to dierences in AFAP-110 expression. In contrast, tyrosine phosphorylated AFAP-110 from Cos-1 cell lysates overexpressing AFAP-110 and Src with several tyrosine-phosphorylated substrates from Src-transformed CEF (data not shown). These data indicate that cYes has the potential to bind AFAP-110 through SH2, but not SH3 interactions. Fusion proteins were quantitated via Coomassie staining to verify that equal amounts were used in the absorptions. In order to con®rm that the inability of the Yes SH3 domain to absorb AFAP-110 re¯ected dierential speci®city and not a defect in the folding or function of the GST-SH3
Yes construct, Western blot analysis with an antibody directed against the Yes SH3 binding partner p65 YAP was performed (Sudol, 1994) . p65 YAP was identi®ed through the use of an anti-idiotypic antibody and was subsequently demonstrated to bind to the Yes SH3 domain in vitro (Sudol, 1994) . Although, p65 YAP is not a tyrosine-phosphorylated substrate, it is detected in complex with cYes in vivo (Sudol, 1994) . Western blot analysis con®rmed that p65 YAP was speci®cally absorbed by the Yes SH3 domain and not the Src SH3 domain or GST alone (Figure 1b) . Thus, the inability of the Yes SH3 domain to anity absorb AFAP-110 did not appear to be due to a functional defect in the GST-SH3 Yes construct. These results demonstrate ligand speci®city between the Src and Yes SH3 domains and raise the possibility that SH3 domain selectivity may serve as a general mechanism ) were grown to con¯uence and lysed in RIPA buer. Twenty micrograms of GST, GST-SH3 Src or GST-SH3 Yes were incubated with 250 mg of Cos-1 cell lysates containing AFAP-110, while GST, GST-SH2 Src , and GST-SH2
Yes were incubated with 250 mg of Cos-1 cell lysates containing tyrosine phosphorylated AFAP-110, as previously described (Guappone et al., 1996) . Bound proteins were eluted by boiling in Laemli's sample buer, resolved by 8% SDS ± PAGE, and subjected to Western blot analysis with the polyvalent anti-AFAP-110 antibody F1 (Guappone et al., 1996) . (b) Anity absorption from 500 mg of CEF cellular lysates with GST, GST-SH3 Src or GST-SH3 Yes , followed by Western blot analysis with an anti-p65YAP polyclonal antibody for directing signaling speci®city between cSrc and cYes.
In order to assess the ability of the SH3 or SH2 domains to aect substrate selection, chimeric Src 527F constructs were created in which the Src SH3 domain (F3), SH2 domain (F2) or both domains (F32), were replaced by the corresponding domains of cYes ( Figure  2 ). Identical chimeras were generated within the context of cSrc (Y3, Y2 and Y32) (Figure 2) , however, in order to facilitate the detection of coimmunoprecipitating proteins, the fully activated versions were used throughout this report. Swapping of functional domains was enabled by the generation of novel restriction sites that de®ne the boundaries separating the SH3 and SH2 domains. Point mutations were veri®ed, and DNA sequence analysis con®rmed that no secondary mutations were encumbered. These chimeras were expressed in chicken embryo ®broblast (CEF) cells using the Rous sarcoma virus vector, along with cSrc and Src 527F . Relative expression levels were determined by Western blot analysis of whole cell lysates with a rabbit anti-Src antibody that recognizes a common epitope in the carboxy terminus of cSrc and Src 527F . As shown in Figure 3a ,b, all constructs were expressed at comparable levels. The Src 527F /cYes chimeras were determined to be fully active based on their reactivity with an antibody that recognizes the phosphorylated version of the cSrc autophosphorylation site Tyr
416
, their ability to transform CEF, and their ability to dramatically increase the tyrosine phosphorylation levels of cellular proteins from total cell lysates (data not shown). The inclusion of normal CEF cell lysates in these and all subsequent Western blots demonstrated the contribution of the overexpressed proteins to the observed results, as compared to endogenous Src family kinases. Western blots of total cell lysates were also probed with a polyclonal anti-Yes antibody (Figure 3c,d ). This antibody showed strong reactivity with the Y3, Y32, F3, and F32 constructs and some limited crossreactivity with constructs containing the Src SH3 domain. The Yes antibody was raised against a region of Yes encompassing the SH3 and SH2 domains and appears to have speci®city for the Yes SH3 domain (Sudol and Hanafusa, 1986) . No antibody was available to discriminate between the Src and Yes SH2 domains, however, restriction enzyme digests of the plasmid cDNA's encoding these constructs, as well as sequence analysis, veri®ed the presence of the cYes SH2 domain coding sequence (data not shown). These data demonstrate that the cSrc/cYes and the Src 527F / cYes chimeras can be expressed in CEF cells by Rous sarcoma virus.
In order to explore the possibility that inecient SH3 and/or SH2 domain interactions were responsible for the previously observed inecient phosphorylation of AFAP-110 and pp130cas by vYes, the ability of activated Src with the cYes SH3 and/or SH2 domains to form stable complex with and induce tyrosinephosphorylation of these proteins was analysed. The steady-state levels of pp130cas and AFAP-110 tyrosine- ). Mutations were engineered using the Quickchange Site-directed Mutagenesis kit (Stratagene). All mutations were engineered such that the corresponding amino acid sequence remained intact. All sequences were veri®ed, along with the absence of second site mutations, by DNA sequencing. The newly engineered restriction enzyme sites were used to facilitate sub-cloning of the SH3 and SH2 domain coding sequences of c-yes into the c-src or Src 257F backbone. The SH3, SH2, or SH3 and SH2 domains of the cSrc and Src 527F were replaced with those of cYes, resulting in constructs of cSrc, cSrc/ cYes SH3 (Y3), cSrc/cYes SH2 (Y2), cSrc/cYes SH3/SH2 (Y32), Scr /cYes chimeras (b and d) were lysed in NP40 or RIPA buer, respectively, and 25 mg of total cell proteins were resolved by 8% SDS ± PAGE and transferred to PVDF (Micron). Western blot analysis with the rabbit anti-Src antibody (1 : 1000 dil.), reactive against a conserved domain in the carboxy-terminus of Src, common to all constructs, was used to demonstrate the expression levels of (a) cSrc, Y3, Y2 and Y32, (b) as well as Src 527F , F3, F2 and F32. Western blot analysis with the rabbit anti-Yes antibody (1 : 2000) , that recognizes a motif speci®c to the cYes SH3 domain, was used to demonstrate the identity of the chimeric constructs (c) Y3 and Y32, (d) as well as the F3 and F32 constructs phosphorylation were assessed from lysates of cells expressing Src 527F and the corresponding chimeras. As seen in Figure 4 , Src 527F and each of the Src 527F /cYes chimeras induced comparable levels of pp130cas and AFAP-110 tyrosine phosphorylation (Figure 4a ,b, top panels). In order to assess the eects of the Yes SH3 and SH2 domains on the ability of Src 527F chimeras to form stable complex with either AFAP-110 or pp130cas, in vivo, Src 527F /cYes chimeras were immunoprecipitated with the mAb EC10 and Western blot analysis was performed with antibodies directed against either pp130cas (anti pp130cas) or AFAP-110 (mAb 4C3). Although no signi®cant reduction in pp130cas binding to the Src 527F /cYes chimeras was detected (Figure 4c, top panel) , F3 and F32, demonstrated a 2.5-fold reduction in their ability to co-immunoprecipitate with AFAP-110, compared to Src 527F and F2 (Figure 4d, top panel) . This correlated well with previous data that indicated SH3 interactions are necessary for stable complex formation between Src 527F and AFAP-110 (Kanner et al., 1991; Guappone and Flynn, 1997) . These results indicate that differential SH3 domain speci®city may direct dierences in steady-state levels of stable complex formation between cSrc and cYes and AFAP-110, in vivo. These results also indicate that the previously observed inecient vYes-induced tyrosine-phosphorylation of AFAP-110 and pp130cas does not appear to be exclusively the result of inecient SH3 or SH2 domain mediated substrate presentation, as these proteins were eciently phosphorylated in vivo by the F3, F2 and F32 chimeras. This result is particularly interesting in the case of AFAP-110, as SH3 domain interactions have been demonstrated to be required for phosphorylation of AFAP-110 by Src in vivo, and the cYes SH3 domain clearly demonstrates a low anity for AFAP-110, both in vitro and via co-immunoprecipitation. However, even the low anity of the Yes SH3 domain for AFAP-110 may allow a transient interaction between the F3 and F32 chimeras and AFAP-110 in vivo that, coupled with the overexpression of the chimeras in comparison to AFAP-110, may be sucient to achieve stoichiometric levels of phosphorylation in vivo.
In order to more generally assess the roles of the SH3 and SH2 domains in directing speci®city in binding to putative substrates, the pro®le of tyrosinephosphorylated proteins in complex with Src 527F and each of the Src 527F /cYes chimeras was examined. Src 527F , F3, F2, and F32 were immunoprecipitated with the rabbit anti-Src antibody, and co-immunoprecipitating tyrosine-phosphorylated proteins were resolved by SDS ± PAGE and visualized by Western blot analysis with an antibody directed against phosphotyrosine. As seen in Figure 5 , a phosphorylated protein of approximately 87 kDa speci®cally co-immunoprecipitated with constructs containing the Yes SH2 domain, F2 and F32. While the identity of this protein is currently unknown, the observation that it coimmunoprecipitates predominantly with chimeras with the Yes SH2 domain suggests that it represents either a direct or indirect Yes-SH2 binding partner. Thus, the Yes SH2 domain may also direct speci®city in binding cellular proteins.
The data presented here indicate that speci®city exists between both the SH3 and SH2 domains of cSrc and cYes. It was not surprising to ®nd dierences in the ligand speci®city of the cSrc and cYes SH3 domains. Previous reports by others indicate differences in the ligand binding capacities of Src family members. In vitro analyses of the optimal peptide sequences bound by SH3 domains of multiple Src family members, including cSrc and cYes, have revealed subtle dierences in the sequences surrounding the core PXXP motif preferred by each family member Sparks et al., 1996) . Weng et al. (1994) demonstrated that the Src, Fyn, and Lyn SH3 domains bound overlapping yet distinct pro®les of proteins in vitro. It has also been shown that the Lck SH3 domain is unable to functionally compensate for the Src SH3 domain in allowing Src to transduce signals from the platelet derived growth factor (PDGF) receptor that result in DNA synthesis (Erpel et al., 1996) . Thus, there is precedent for dierential SH3 domain speci®city between Src family members. Little prior data existed however, to suggest dierences in the binding speci®city of the SH2 domains of Src family members. In vitro studies have shown that Src family members optimally bind cognate ligands having the sequence pYEEI (Songyang et al., 1993; Sicilia et al., 1998) . However, this is merely an optimized sequence obtained using short peptides as cognate ligands, and thus cannot accurately re¯ect how the sequence is presented in the context of a complete protein. The ability of both the cYes and cSrc SH2 domains to eciently bind AFAP-110 in vitro, and the ability of the F2 and F32 constructs to coimmunoprecipitate with pp130cas suggests that there is functional redundancy between the cSrc and cYes SH2 domains. However, the fact that pp87 coimmunoprecipitates only with constructs with the Yes SH2 domain suggests strongly that it is associated, either directly or indirectly, with the Yes but not the Src SH2 domain. This in turn points toward ligand speci®city between the cSrc and cYes SH2 domains. Future studies will determine the signi®cance of stable complex formation with AFAP-110 and pp87, and if the dierential abilities of Src and Yes to associate with these proteins correlates with any of the known functional dierences between cSrc and cYes. The molecular determinants of speci®city between the SH3 and SH2 domains of cSrc and cYes, and the remaining Src family members, remain unclear. The cSrc SH3 and SH2 domains are highly homologous to those of cYes, however, single amino acid changes can be sucient to alter the speci®city of both the SH3 and SH2 domains (Marengere et al., 1994; Weng et al., 1995) . The SH3 domains of cSrc and cYes dier by only 12 of 60 amino acids, while the SH2 domains dier at 29 or 102 residues. The cSrc and cYes SH3 and SH2 domains are highly conserved in their core ligand-binding sites, but non-conservative changes exist between the SH3 domains in the n-Src and RT loops that¯ank the hydrophobic binding pocket and between the SH2 domains in the pY+3 binding pocket. The contributions of amino acid changes in these regions toward dierential ligand binding are under investigation. Elucidation of the contribution of speci®c amino acids toward SH3 and SH2 domain speci®city between Src and Yes may lead to the design of rational drugs capable of speci®cally blocking the unique signaling pathways utilized by these kinases. Such drugs would be ideal for studying the biological pathways aected by individual Src family members and may prove bene®cial in the treatment of cancers in which Src or Yes is abnormally activated, as they could avoid the potentially deleterious eects of inhibiting the function of multiple Src family members.
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